Our CEO Michael Lukesch is heading to Basel to present at the Antibody Engineering &
Therapeutics Europe conference.

We will be presenting a scientific deep-dive into our GoldenSite™ conjugation platform –
the technology we are building to solve ADCs most persistent problem: Limited therapeutic
windows.